France
TreeFrog Therapeutics has developed proprietary C-Stem technology, enabling the mass production of induced pluripotent stem cells and their differentiation into transplantable microtissues. This breakthrough technology provides unprecedented scalability and cell quality, positioning the company as a leader in the field of regenerative medicine.
In 2021, the company secured a significant investment of $82M to advance its pipeline of stem cell-based therapies, focusing on the lead program in Parkinson's Disease. To support its growth, TreeFrog Therapeutics established a technological hub in Boston, USA in 2022, aiming to promote the adoption of C-Stem and to initiate co-development partnerships with key academic, biotech, and industry players in the field of cell therapy.
Notably, the most recent investment of €30.00M in debt financing was secured on 27 May 2025, with the European Investment Bank participating as the investor.
With a focus on Biopharma, Biotechnology, and Health and Wellness industries, TreeFrog Therapeutics is poised to make significant contributions to the advancement of cell therapies and regenerative medicine.
Garuda Therapeutics
